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Hereditary leiomyomatosis and renal cell carcinoma (HLRCC) syndrome-associated RCC are 
difficult to diagnose prospectively. We used immunohistochemistry (IHC) to identify FH 
(Fumarate Hydratase)-deficient tumors (defined as FH negative, 2-succinocysteine (2SC) 
positive) in cases diagnosed as “unclassified RCC, high grade or with papillary pattern”, or 
“papillary RCC type 2”, from multiple institutions. 124 tumors (from 118 patients) were 
evaluated by IHC for FH and 2SC. An FH deficiency was found in 24/124 (19%) cases. An 
indeterminate result (only one marker abnormal) was found in 27/124 (22%) cases. In a TMA of 
776 RCCs of different types, only 2 (0.5%) tumors, initially considered papillary type 2, were 
FH-deficient. FH mutations were found in 19/21 FH-deficient tumors (9 confirmed germline) 
and in 1/26 FH indeterminate tumors identified by IHC. No FH mutations were found in 2/21 
FH-deficient RCC, 25/26 FH indeterminate RCC and 10/10 RCC demonstrating FH expression 
by IHC. Patients with FH-deficient RCC had median age of 44 years (range 21 to 65). Average 
tumor size was 8.2cm (range 0.9 to 18cm). FH-deficient RCC were characterized by at least 
focal macronucleoli and demonstrated two or more growth patterns in 93% cases. Papillary was 
the most common (74%) and dominant (59%) pattern, while other common patterns included: 
solid (44%), tubulocystic (41%), cribriform (41%) and cystic (33%). At presentation, 57% were 
stage ≥pT3, 52% had positive nodes, and 19% had distant metastases. After mean follow-up of 
27 months (range 1-114 months), 39% of patients were dead of disease and 26% had disease 
progression. We conclude that FH and 2SC are useful IHC ancillary tools which allow 








































































Hereditary leiomyomatosis and renal cancer syndrome (HLRCC) is an autosomal dominant 
disorder characterised by inherited predisposition to uterine and cutaneous leiomyomas and renal 
cell carcinoma (RCC). It is characterized by inactivating germ-line mutation in the fumarate 
hydratase (FH) gene, which is located at 1q42.3-q43 and codes for an enzyme involved in the 
tricarboxylic acid cycle, which hydrates fumarate to form malate. (1-6) Although the hereditary 
association with multiple leiomyomas of the skin has been known for more than 60 years 
now,(7) the first syndromic association of uterine and skin leiomyomas with renal carcinoma was 
reported in 2001 in two families from Finland.(2, 5) HLRCC-associated RCC was included in 
the 2004 WHO classification of renal neoplasms (8), however not as a distinct RCC subtype, but 
as a presumed hereditary counterpart of papillary RCC type. Subsequent publications highlighted 
the aggressive behaviour of the renal carcinomas associated with HLRCC syndrome and 
expanded its morphologic spectrum, emphasizing the presence of orangiophilic or eosinophilic 
macronucleoli with perinucleolar halos (viral inclusions-like).(9, 10) HLRCC syndrome-
associated RCC is currently recognized as a separate entity in the 2013 International Society of 
Urological Pathology (ISUP) Vancouver Classification of renal tumors(11) and it is included in 
the upcoming WHO classification 2016. 
 
Biallelic inactivation due to FH mutations in HLRCC syndrome results in either complete loss or 
reduction of the FH enzymatic activity, which leads to accumulation of the intracellular levels of 
fumarate.(4, 12) The increased level of fumarate modifies the cysteine residues in many proteins, 
resulting in increased protein succination and production of S-(2-succino)-cystein (2SC), which 




































































levels of 2SC, resulting in positive 2SC immunohistochemistry (IHC) staining, was shown to be 
highly specific for detection of HLRCC-associated RCC.(14) The loss of FH enzymatic activity, 
resulting in negative fumarate hydratase staining on IHC was also demonstrated to have a high 
specificity in identifying HLRCC-associated tumors.(15, 16) However, a combined IHC 
approach to investigate the utility of both 2SC and FH antibodies in detecting previously 
unknown HLRCC-associated RCC has so far not been reported.  
 
Although the primary morphologic pattern described in HLRCC-associated RCC is papillary, 
these tumors have been shown to demonstrate many growth patterns, often in combination, 
which can also present a diagnostic challenge when evaluating neoplasms with unknown clinical 
or familial background.(9, 10, 14) Because of their rarity and diagnostic difficulties in 
identifying these tumors, we postulated that many of them are currently under recognized, under 
reported or misclassified and we sought to evaluate the utility of IHC for 2SC and FH in 
identifying these tumors, particularly in cases signed out either as “unclassified RCC, high 
grade”, “unclassified RCC with papillary pattern”, or “type 2 papillary RCC”. We also describe 
the pathological features, FH mutational status and the clinical features of RCCs demonstrating 
lack of FH expression (fumarate hydratase-deficient RCC), characterized by FH negative and 
2SC positive staining on IHC. 
 
Material and Methods 
 An institutional Ethics Review was obtained for the study.  
 




































































We initiated an international collaboration and deliberately searched for renal neoplasms labelled 
in the initial sign-out as “unclassified RCC, high grade” or “unclassified RCC with papillary 
pattern” or type 2 papillary RCC. In particular, we searched for tumors exhibiting: 1) aggressive 
features, such as invasion into perirenal or sinus fat and/or showing regional metastatic disease; 
2) at least focal macronucleoli, and 3) presence of different growth patterns, all of which were 
previously associated with HLRCC-associated RCC. Although many of the participating 
collaborators had large in-house and consult practices with subspecialty interest in urologic 
pathology, the search of the respective institutional databases was subject to varying digital 
archive limitations for retrospective searches. All potential cases were reviewed by two urologic 
pathologists and a representative tissue block was retrieved for additional studies. We also 
included 2 previously confirmed and published HLRCC-associated RCC.(17, 18) 
Clinicopathologic and follow-up data were collected on cases demonstrating IHC profile 
compatible with FH deficiency, by review of the institutional records and by contacting the 
consulting pathologists.  
 
TMA evaluation of papillary RCC enriched cohort 
Using tissue microarray (TMA) methodology, a total of 776 renal neoplasms from three separate 
institutions were evaluated by IHC for FH and 2SC. TMAs were enriched for papillary RCC 
(381), comprising 175 papillary RCC type 1, 68 type 2, 39 mixed and 99 papillary RCC, not 
specified. TMAs also included other renal tumor types: clear cell RCC (232), chromophobe RCC 
(21), oncocytoma (25), other RCC (39), and urothelial carcinoma (78). TMAs were constructed 





































































FH and 2SC Immunohistochemistry 
IHC for FH and 2SC was performed in one laboratory on formalin fixed paraffin embedded 
(FFPE) sections. We used a commercially available primary anti-FH mouse monoclonal 
antibody (1 in 2000 dilution; clone J-13, cat no sc-100743, Santa Cruz Biotechnology, USA) and 
an anti-2SC rabbit polyclonal antibody (1:2000, antibody provided by Dr. Norma Frizzell) on an 
automated staining platform—the Leica Bond III Autostainer (Leica Biosystems, Mount 
Waverley, Victoria, Australia).  For FH, heat induced epitope retrieval (HIER) was performed 
for 30 minutes at 97 degrees Celsius in the manufacturer’s alkaline retrieval solution ER2 (VBS 
part no: AR9640). For 2SC, HIER was performed for 30 minutes at 97 degrees Celsius in the 
manufacturer’s acidic retrieval solution ER1 (VBS part no.AR9961). 
 
FH and 2SC IHC were scored independently by two pathologists (KT and AG) on whole slide 
sections from tumors with “unclassified, high grade”, or “unclassified with papillary pattern” 
diagnosis, as per study design. Absent staining for FH in the neoplastic cells, in the presence of a 
positive internal control in blood vessels, inflammatory cells, other stromal cells, and non-
neoplastic cells of the kidney parenchyma was interpreted as true negative staining (loss or FH-
deficient status). All other patterns of staining were considered positive, provided the staining 
was cytoplasmic and granular (that is mitochondrial). Staining for 2SC on cases evaluated on 
whole section was scored as negative (0); (1+) if focal (<50% of cells reactive) or diffuse (>50% 
of cells reactive) but of weaker intensity; or (2+) if diffuse positive (>50% of cells reactive) with 
moderate to strong intensity. In positive 2SC cases, we also attempted to localize the reactivity 
(cytoplasmic, nuclear or both). Negative staining in the adjacent normal renal parenchyma was 
considered an internal negative control. Due to the limited amount of available tissue in the TMA 





































































Positive IHC result was considered when both antibodies showed pattern indicating FH 
deficiency (FH -, 2SC 2+); negative IHC result was when FH antibody showed retained FH 
expression and 2SC was not expressed (FH +, 2SC 0). Indeterminate IHC result, was considered 
when only one of the markers showed aberrant expression status suggesting FH deficiency, while 
the other was equivocal or negative (FH +, 2SC 1+ to 2+; or FH -/+, 2SC 2+). 
 
Molecular evaluation of FH mutations 
All cases with available tissue that demonstrated FH deficiency (FH -, 2SC 2+) or showed 
indeterminate result (only one antibody reactive), underwent molecular evaluation of FH gene 
mutation status by Sanger sequencing and loss of heterozygosity (LOH) studies on DNA 
extracted from macrodissected FFPE tissue. We also evaluated 10 cases with retained FH 
expression for FH mutation, as a negative control group. For Sanger sequencing previously 
described custom primer sets were used and the whole coding sequence including exon-intron 
junctions was sequenced using primers designed to produce short amplicons suitable for 
degraded formalin-fixed DNA.(19) LOH studies were performed using a previously described 
set of six polymorphic short tandem repeat markers (D1S517, D1S2785, D1S180, AFM214xe11, 
D1S547 and D1S2842), surrounding the FH gene.(19) Additional patients with suspected 
HLRCC were offered FH germline testing as part of their clinical care. This clinical genetic 
testing was performed using massively parallel sequencing for small nucleotide variants with 
Sanger confirmation and Multiplex Ligation-dependent Probe Amplification (MLPA) for 







































































Pathology evaluation of cases by FH and 2SC immunohistochemistry 
Over 3000 cases from multiple institutions were reviewed to select possible study cases that 
fulfilled the search criteria (spanning the years 1996-2014). We identified 124 tumors (from 118 
patients) for additional IHC evaluation by FH and 2SC using representative whole slide sections. 
Most of the re-reviewed cases not included in the study remained “unclassified” after review, but 
additional IHC or other testing was not performed on excluded cases to further assess their 
classification. An IHC result indicating FH deficiency (FH -, 2SC 2+) was found in 24/124 
(19%) cases (Fig. 1A-C) and 73/124 (59%) showed retained FH function by IHC (FH +, 2SC 0) 
(Fig. 1D-F). Indeterminate IHC profile, when only one of the markers was suggestive of FH 
deficiency (FH + with 2SC 1+ to 2+; or FH -/+ with 2SC 2+) was found in 27/124 (22%) cases 
(Fig. 2A-F). All FH negative cases (FH score 0) also demonstrated diffuse strong positive 
staining for 2SC (2SC 2+). In the FH-deficient cases, 2SC (2+) was diffusely and strongly 
positive in the cytoplasm in all cases; in only 35% of cases a distinct nuclear staining could be 
confirmed, while in the remaining cases the nuclear staining was difficult to evaluate due to 
strong cytoplasmic reactivity. In the cases considered indeterminate for FH expression, 2SC 
reactivity was restricted only to the cytoplasm. 
 
TMA evaluation by FH and 2SC immunohistochemistry 
Of the TMA evaluated cases, only 2/381 (0.5%) papillary RCC, both initially considered type 2 
(pt #2 and #17) (3% of all type 2 papillary RCC), showed FH deficient result (FH -, 2SC 2+) 
(Fig. 3A-C). All other tumor types evaluated on TMA, which included 232 clear cell RCC, 21 




































































retained FH expression, which was somewhat variable, but typically of moderate to strong 
intensity, while the corresponding 2SC staining was considered negative in all evaluated cases 
(FH+, 2SC 0).  
 
Molecular evaluation of FH mutations 
The IHC results for FH and 2SC for FH-deficient cases and the corresponding FH mutational 
alterations are shown in Table 1. We performed molecular testing on 64 cases, of which 57 
produced informative result. We analyzed 21/26 cases considered FH-deficient by IHC (24 
identified on whole slide and 2 on TMA by IHC). We also evaluated 26/27 cases considered FH 
indeterminate by IHC and 10/73 cases which showed retained FH expression by IHC.  
 
Mutations were found in 19/21 FH-deficient tumors, while in 2 cases mutations could not be 
identified (one had low DNA quality and in neither case were large scale deletions sought by 
MLPA). 9/19 cases underwent germline testing and the FH mutations were confirmed germline 
in all tested cases, while the remaining 10/19 cases, which harboured FH inactivating mutations, 
had only neoplastic FFPE tissue available for testing and germline mutations could not be 
confirmed. Of 26 FH indeterminate tumors, only 1 case demonstrated FH mutation with IHC 
profile: FH -/+, 2SC 2+ (Figure 2D-F), but no specific germline testing was performed. The 
remaining 25/26 demonstrated wild type FH (IHC profile: 21 (FH +, 2SC 1+); 3 (FH +, 2SC 2+); 
and 1 (FH -, 2SC 2+). All 10 cases with normal FH function (FH+, 2SC 0) by IHC showed wild 
type FH.  
  




































































The clinico-pathologic findings in 27 FH-deficient RCC are shown in Table 2. They were almost 
twice as common in men (M:F=1.9:1), with a median patient age of 44 years (mean 44; range 21 
to 65 years). Twenty-one patients were Caucasians; one patient each was Asian and African-
American. Skin leiomyomas were documented in 3/23 (13%) patients and 5/8 (63%) female 
patients had prior uterine leiomyomas; of note, FH was also negative by IHC in 2/2 females with 
tested uterine leiomyomas. Family history of either renal tumors, skin or uterine leiomyomas was 
elicited in 6/23 (26%) patients. Overall, an association with HLRCC syndrome was documented  
in 8/23 (35%) patients, based on the presence of skin and uterine leiomyomas in the patients or 
their kindreds, familial history of syndromic features, and FH mutational alterations. There was a 
predilection for the left kidney (L:R=1.5:1). Solitary tumors were found in 21/23 (91%) patients 
and 2 patients had bilateral tumors (one had multiple neoplasms in both kidneys). Average tumor 
size was 8.2cm (median 8.5cm, range 0.9 to 18cm). 57% of patients had stage ≥pT3 and 52% 
had positive nodes at surgery; in 19% patients distant metastatic disease (M1) was also found at 
presentation. After a mean follow-up of 27 months (median 17.5, range 1-114 months), 39% 
(9/23) patients were dead of disease and 26% (6/23) had disease progression, with evidence of 
local recurrence or subsequent regional or distant metastases.  
 
The 27 FH-deficient neoplasms were characterized by variable and different architectural growth 
patterns and typically two or more patterns were found in 93% of cases, as shown in Table 3. 
Although papillary pattern was most commonly present and seen in 74% of cases (in 59% as a 
dominant one), other common patterns were also seen: solid in 44%, (dominant in 22%), 
tubulocystic in 41% (dominant in 7%), cribriform in 41% (dominant in 4%) and cystic in 33% 




































































showed sarcomatoid differentiation as a dominant morphology. Examples of different 
morphologic growth patterns are illustrated in Figure 4A-F. By design, all cases demonstrated at 
least focal macronucleoli, which in some cases were ubiquitous. In cases with papillary pattern, 
typically there was absence of foam cells in the fibrovascular cores; hyalinization of the 
fibrovascular cores was noted in 9 (45%) cases.  
 
Discussion 
In this study we demonstrated that one fifth of RCC, diagnosed either as “unclassified RCC, high 
grade” or “unclassified RCC with papillary pattern”, are FH-deficient by IHC and were almost 
invariably accompanied by FH mutations. Only 0.5% of all cases diagnosed previously as 
papillary RCC, and 3% of those considered type 2 papillary RCC, showed FH-deficiency by IHC 
and FH mutations, while all other evaluated renal tumors showed retained FH expression. The 
FH-deficient RCCs shared remarkable clinico-pathologic similarities with HLRCC-associated 
RCC, including younger age at presentation, aggressive clinical behaviour and adverse 
morphologic features, and were characterized predominantly by papillary architecture, typically 
admixed with other growth patterns, with invariable presence of at least focal macronucleoli. In 
fact, we were able to document an association with HLRCC syndrome in 8/23 (35%) of patients. 
By IHC, these tumors typically demonstrated FH-deficient profile (FH -) with aberrant 
succination, resulting in diffuse and strong 2SC reactivity (2+), which has previously been 
shown to be strongly associated with HLRCC-related RCC.(13, 14) The IHC profile, along with 
the morphology, aggressive clinical behaviour, and the presence of FH mutations, provide strong 





































































We believe that both antibodies, FH and 2SC, should be used simultaneously to enhance the IHC 
potential in detecting FH-deficient RCC. Combined negative staining for FH and strong positive 
staining for 2SC demonstrated very good sensitivity for FH-deficient RCC profile and excellent 
specificity. That is, a normal pattern of staining for FH and 2SC can be used to rule out FH 
deficiency in the great majority of renal carcinomas encountered.  However, we identified 2 
tumors (patient #19 and #21, 2nd tumor) with variably retained FH expression by IHC; both 
tumors showed FH point mutations (2SC 2+ in both cases). As previously shown, possible 
missense or other in-frame FH mutations may be associated with retained FH expression, 
resulting from a synthesis of a stable, but inactive enzyme.(13-15, 20) In addition, all cases 
considered “indeterminate” on IHC due to 2SC 1+ (21 cases) or 2SC 2+ (3 cases), but showing 
retained FH expression (FH +), exhibited wild type FH. Therefore, restricting the evaluation to 
only one of the antibodies would be limited by the relatively lower sensitivity of FH and the 
lower specificity of 2SC. We also found it difficult to reliably confirm if 2SC reactivity was 
nuclear, when diffuse and strong cytoplasmic reactivity was present. This is in contrast to Chen 
Y-B et al(14) who found both cytoplasmic and nuclear 2SC to be present in HLRCC-associated 
RCC, allowing them to distinguish it from the “cytoplasmic only” pattern observed in a 
proportion of papillary RCC, type 2 and some unclassified, high grade RCC cases. The clinical 
utility of the 2SC antibody is also currently limited, because it is not yet commercially available 
and cannot be routinely used in surgical pathology laboratories. Given the lower specificity and 
the difficulty in interpretation of 2SC, negative FH appears to be a more specific and comparably 





































































Recent studies have also shown that IHC reactivity for 2SC(21) or 2SC in combination with FH 
(20, 22) aid in identifying FH-deficient leiomyomas in younger patients, associated with HLRCC 
syndrome. We have previously shown that although the great majority of patients with HLRCC 
syndrome will have FH deficient leiomyomas, 1% of all sporadic uterine leiomyomas are FH 
deficient usually due to somatic inactivation.(22) This is in contrast to the current study, where 
germline FH mutations were identified in all patients with FH-deficient RCC with sufficient 
material for testing.  
 
The RCC associated with HLRCC syndrome have been reported in about 30% of HLRCC 
families.(4, 12) HLRCC-associated RCC are particularly difficult to manage because they are 
highly aggressive and present with advanced stage and metastatic disease, resulting in death of 
disease in 40-50% patients.(9, 10) Therefore, active surveillance is not recommended for the 
management of even small HLRCC-associated renal tumors in families with HLRCC syndrome, 
and wide surgical excision is recommended when any renal tumor is detected.(10) RCC 
associated with HLRCC syndrome are however quite rare and clinically challenging to diagnose 
in practice, because patients frequently do not exhibit the whole spectrum of the clinical 
presentations and the family association is either unknown or not apparent; clinical 
manifestations can also differ within families (9, 10) The initial report described renal tumors in 
32% of the patients, all with metastatic disease at presentation,(2) with a prevalence of 14% 
reported by the National Cancer Institute (NCI) group in a North American cohort.(4) Kidney 
cancers have lower penetrance than the skin or uterine leiomyomas in the HLRCC affected 
families and they typically occur more than a decade later.(4, 9, 12) Therefore, patients may 




































































carcinoma, and renal tumors may demonstrate a delayed presentation or the patients may lack the 
other HLRCC syndromic features. In the largest cohort of 38 patients with renal tumors, reported 
by Merino et al from the NCI, 39% had documented skin leiomyomas and 55% had uterine 
leiomyomas.(9)  The morphology remains crucial in recognizing these tumors in routine practice.  
 
In a recent study of comprehensive molecular characterization of papillary RCC, 3.1% (5/161) of 
all papillary RCC and 8.3% (5/60) of those diagnosed as papillary type 2, demonstrated germ-
line or somatic FH mutations, which were associated with the CpG Methylator Phenotype 
(CIMP).(23) Similar to our study, these patients were younger at presentation, and had a lower 
probability of overall survival than other patients with papillary RCC. A subset of these papillary 
RCC type 2 tumors, designated as CIMP-associated, shared the FH-deficient profile observed in 
HLRCC-associated RCC, based on their molecular features, allowing for more accurate 
characterization, which may lead to disease-specific targeted therapies.(23) This also highlights 
the fact that the differential diagnosis of FH-deficient RCC will typically include papillary RCC 
type 2, which is a relatively common renal tumor. However, the frequent papillary morphology 
in combination with additional architectural patterns, and at least focal presence of 
macronucleoli, should be regarded as morphologic clues to undertake additional IHC testing for 
FH and 2SC in this setting.  
 
Currently, there is a lack of uniformly accepted definition of HLRCC-associated RCC, which is 
defined not just by mutational analysis, but also clinically. The NIH definition requires that the 
diagnosis of HLRCC is established with the identification of a heterozygous pathogenic variant 




































































confirmed leiomyoma, a single leiomyoma in the presence of a positive family history of 
HLRCC, and/or one or more tubulo-papillary, collecting-duct, or papillary type 2 renal tumors 
with or without a family history of HLRCC. For the time being, “FH-deficient RCC” may be the 
most appropriate nomenclature for tumors that show IHC negative staining for FH and strong 
2SC reactivity, in the setting of uncertain clinical and family history and unknown genetic 
status.(24) Taking a pragmatic approach, we would recommend that if FH-deficient RCC is 
diagnosed, the possibility of HLRCC should be first considered clinically. If there is a suggestive 
personal or family history, a presumptive diagnosis of HLRCC can be made pending 
confirmation with formal genetic counselling and germline mutation testing. When FH-deficient 
RCC is diagnosed in the absence of features suggesting syndromic disease, there is little data to 
indicate the risk of germline mutation. Based on our limited data (the finding of germline FH 
mutation in all 9 patients who had sufficient material available for testing), at this stage we 
believe the risk of germline mutation (that is HLRCC) is very high, and therefore performing 
genetic counselling and mutational analysis would be appropriate in all patients with FH-
deficient renal carcinoma. This recommendation may be modified in the future if, similar to FH-
deficient uterine leiomyoma, a low rate of germline mutation is found in follow-up studies. 
 
The tumorigenic effect of mutated FH results in fumarate accumulation, which acts as a 
metabolic tumor suppressor,  resulting in a metabolic shift toward aerobic glycolysis with 
decreased oxidative phosphorylation (so-called Warburg effect). It has been postulated that this 
alteration has possible downstream effects by inhibiting the hypoxia inducible factor prolyl 
hydroxylase and increasing the hypoxia-inducible factor 1 alpha (HIF1alpha), which targets 




































































1(GLUT1), and produces additional epigenetic alterations of genome-wide histone and DNA 
methylation, leading to increased cell proliferation and tumorigenesis.(3, 24-26) On a molecular 
level, these changes have also been characterized by increased oxidative stress and activation of 
the NRF2-antioxidant response elements (ARE) pathway.(23, 27, 28) 
 
Limitations of this study include its retrospective nature, which allowed us to confirm association 
with HLRCC syndrome only in about a third of patients with FH-deficient RCC. For example, in 
some cases we were not able to obtain a dermatological confirmation of skin leiomyomatosis, 
and a complete family history on specific HLRCC features was not available. Although 
mutational analysis was performed on FFPE neoplastic tissue in the majority of tested cases, a 
formal FH genetic testing was done only in a subset of cases, perhaps with a selection bias 
towards patients with a high likelihood of familial disease, limiting the ability to confirm 
germline FH mutations. In 2 FH-deficient cases by IHC, we could not confirm the presence of 
FH mutations; one of the 2 cases demonstrated low DNA quality and additional studies to 
investigate for possible FH mutations in these 2 cases, for example, by MLPA to screen for large 
scale FH deletions were not performed. 
 
In summary, we found that a substantial number of cases considered either as “unclassified RCC, 
high grade” or “unclassified RCC with papillary pattern”, and small percent of cases diagnosed 
as papillary RCC type 2, demonstrated FH-deficient pattern (FH -, 2SC 2+) by IHC and were 
invariably accompanied by FH mutations at the molecular level. Although we could document 
an unequivocal association with HLRCC syndrome in only about a third of the patients, there is 




































































Furthermore, even apparently sporadic FH-deficient RCC show striking clinico-pathological 
similarities to unequivocally HLRCC syndrome-associated renal carcinomas, including a 
younger age and adverse features at presentation, aggressive clinical behaviour, and frequent 
papillary architecture in combination with other growths patterns, with invariable presence of at 
least focal macronucleoli. In addition to the careful morphologic evaluation, IHC for FH and 
2SC is a useful aid that allows recognition of the RCC with FH-deficient profile with FH IHC 





































































Figure 1  
An FH-deficient RCC showing a papillary growth pattern (A). The cells exhibit eosinophilic 
macronucleoli with perinucleolar clearing (inset) (patient #6). On IHC, neoplastic cells 
demonstrate FH negative staining, while non-neoplastic cells show granular cytoplasmic 
staining, used as positive internal control (B). 2SC shows diffuse and strong staining in the 
neoplastic cells (2+) (C). In cases with retained FH expression, such as in this example with 




Some cases demonstrated indeterminate IHC profile for FH, with only one of the markers 
suggestive of FH deficiency while the other was equivocal or negative. In this example showing 
papillary growth (A), FH demonstrated retained expression (B), while 2SC showed variable 
staining pattern (1+) (C); no FH mutation was identified on molecular analysis. In another 
example with indeterminate IHC profile (D), FH showed focal expression (E), but 2SC was 
diffusely positive (2+) (F). On molecular analysis, FH mutation was identified in this case 
(patient #19).  
 
Figure 3 
We identified 2 cases on TMA with FH-deficient pattern, originally considered papillary RCC 
type 2 (A). Both cases showed prominent eosinophilic nucleoli (inset). In both cases, FH was 
negative (B), while 2SC was strongly positive (C). FH mutation was confirmed in the illustrated 







































































FH-deficient RCC were characterized by various architectural growth patterns with two or more 
patterns present in great majority of cases. Papillary pattern was most commonly present as a 
dominant one (A) and hyalinization of the papillary fibrovascular cores was frequent (B). In this 
example, an admixed tubulocystic pattern is also seen (right) (B). Other frequent patterns 
included solid, in this example with foci resembling collecting-duct carcinoma (C), cribriform 
(D), cystic, which in this example also shows intracystic papillary growth (E) and tubular, which 
in this example shows multiple intracytoplasmic vacuoles imparting admixed cribriform 
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TABLE 1. FH and 2SC immunohistochemistry and FH molecular alterations in fumarate hydratase-deficient RCC  
 
Patient FH IHC 2SC IHC FH mutation status  
1 - + + c.1189G>A, p.Gly397Arg 
2 - + + c.174_177dupTGAAA, p.Leu60Ter 
3 - + + c.496G>T, p.Gly166Ter 
4 - + + Large scale deletion of whole of FH on MLPA (Germline)  
5 - + + c.413_414del, p.Leu138fs (Germline) 
6 - + + Large scale deletion of FH and OPN3 gene on MLPA (Germline) 
7 - + + c.689A>G, p.Lys230Arg (Germline) 
8 - + + NA (pt deceased before consent) 
9 - + + c.239dupA, p.Ile81AspfsTer14 
10 - + + Negative 
11 - + + c.911_917 del CTTTTGT(Phe 305Leufs*22) 
12 - + + NA 
13 - + + c.1385_1390+6del 
14 - + + NA 
 
- + + Negative (low quality DNA) 
15 - + + LOH positive (FH wt, sample with abundant non-tumor tissue) 
16 - + + c.395_398delTAAAT, p.Leu132Ter 
17 - + + c.805delA, p.Ile269fsTer15 
18 - + + NA 
19 -/+ + + c.139C>T, p.Gln47Ter 
20 - + + c.320A>C, p.Asn107Thr (Germline) 
21 - + + c.698G>A, p.Arg233His (Germline) 
 
+ + + c.698G>A, p.Arg233His 
    22 - + + c.1189G>A, p.Gly397Arg (Germline) 
 
- + + c.1189G>A, p.Gly397Arg (Germline) 
 
- + + c.1189G>A, p.Gly397Arg (Germline) 





TABLE 2. Clinical characteristics of patients with fumarate hydratase-deficient RCC 
Pt Sex Age Leiomyomas Family History Side 
Greatest 
size (cm) 




1 M 65 No Unk L 18 T3aN1 Liver, lung, spleen and bone at presentation 3 DOD  
2 M 62 Unk Unk L 10 T2aN0 
 
114 AND 
3 M 60 No Unk R 8 T2aNX 
 
7 AND 
4 F 25 Uterine at 25 (FH-) Yes* R 4 T1aNX 
 
17 AND 
5 M 44 Unk Yes†  R 4.5 T3aN0 
 
7 AND 
6 M 25 Skin Yes‡ R 14 T3aN1 Liver, flank wall at 6 months 64 DOD 
7 F 32 Uterine Yes§ L 3 T1aNX Left para-aortic lymph nodes 56 AWD 
8 M 35 Unk Unk R 10 T3aN1 Para-aortic lymph node 18 DOD 
9 M 51 Unk Unk R 14 NA 
 
96 AND 
10 M 46 Unk Unk L 10 T3aN1 Bone (multiple) 24 DOD 
11 M 44 Unk Unk NA 8 NA Lung, lymph nodes at 6 months 6 AWD 
12 F 40 Unk Unk L 9 T3aN1 
Peritoneum, retroperitoneum,  lymph nodes, 
omentum 
24 DOD 
13 M 52 Unk Unk R 14 T4N1 Lung, mediastinum 13 DOD 
14 M 41 No Unk L** 1 T1aNX 




42 No Unk L 4 T3aN1 Perihilar lymph node 13 
 
15 F 21 No Yes¶  L 5.5 T3aNX 
 
12 AND 
16 M 42 Unk No L 10 T2N0 Aorta involvement 18 DOD 
17 M 21 No Unk L 5 T4N1M1 Bone (rib), retroperitoneal nodes 4 AWD 
18 M 46 Unk Unk NA NA T3bN1M1 NA 12 DOD 
19 F 50 Unk Unk L 10.9 T2N0 
 
18 AND 
20 F 59 Skin, uterine Unk L 12.5 T4N1M1 
Liver, lung, supraclavicular and iliac lymph nodes 
(direct into adrenal, pancreas) 
1 DOD 










22 M 56 No Unk R 3.5‡‡ T3aN0 
 
31  AWD 
 
M 56 No Unk L 9 T2aNX 
   
 
M 57 No Unk R 4 T1aNX Probable local recurrence (same side tumor) 
  
23 F 43 Uterine at 38 (FH -) Unk L 12.5 T3aN1M1 Bone (tibia) 1 AWD 
Abbreviations: DOD=died of disease, AWD=alive with disease, AND=alive no disease, NA=not available, Unk=unknown 
*Uncle had kidney removed in 2009 for multiple tumours; †Twin brother died from metastatic 'kidney cancer'; ‡Mother with multiple uterine leiomyomas, grandfather died of renal 
carcinoma and had multiple skin lesions (not further characterised); §Mother and one sister tested positively for FH gene; ¶Father and paternal grandmother with “skin lesions”; 
#Maternal aunt with “renal tumors”; **Two similar RCC resected from left kidney (second after 12 mo); ††Bilateral multiple renal tumors; ‡‡Bilateral renal tumors, second tumor on 
in the right kidney possibly local recurrence 
 
TABLE 3. Morphologic patterns seen in fumarate hydratase-deficient RCC. Dominant patterns are marked by asterisk. 
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